Juan Gonzalez Alvarez

Did you know that in the next 5 years there will be an estimated +$90B net sales lost in the US due to LOE? Many of the industries largest brands and classes will be impacted. Loss of exclusivity for a brand is not the end! Strategies can be used to help preserve patient volume and brand value. Check out our latest blog in IQVIA's Brave New World thought leadership series on how to find success in modern markets. We outline seven modern market strategies that manufacturers are using as brands near the end of their patent life. https://lnkd.in/eyBxfPgw Thanks to the authors and team for another great article! #SashaLauks #RossPerak #CollinGe #DanielLuft #JamieCatell

92

1 Kommentar

💡 Valuable input to the ongoing discussion on equitable access to medicines: Roche CEO Thomas Schinecker highlighted that it would be “very easy” to cut US drug prices by 50%—by removing intermediaries and enabling direct-to-patient distribution. According to Schinecker, half of supply chain earnings currently go to middlemen who take “zero risk” in the innovation process. This dialogue underscores a key challenge: ensuring broad access to life-saving therapies while preserving the necessary incentives for those who invest heavily and take the scientific and financial risks to innovate for patients in need. HealthcarePolicy #PharmaInnovation #DrugPricing #AccessToMedicine #Biopharma

83

8 Kommentare

Several health challenges are complex and often go unnoticed. To overcome them, innovation, technology, and collaboration are essential.  One example is MASH, an advanced form of fatty liver buildup. This condition, which affects around 32 million people in Latin America, is challenging to be diagnosed and can lead to serious complications such as cirrhosis, liver cancer, and cardiovascular diseases.  On the other hand, systemic inflammation is associated with a higher risk of heart problems. This is another serious issue for Latin America, as it is estimated that between 9% and 11% of this adult population lives with cardiovascular diseases.  To develop innovative solutions for the prevention, diagnosis, and monitoring of these conditions, MIT Hacking Medicine is coming to Brazil for the first time, in partnership with Massachusetts Institute of Technology, Hospital Israelita Albert Einstein, and supported by Novo Nordisk.  This is an opportunity for professionals from various fields to come together and transform the health future. Registration is free and open until August 17th. Learn more and sign up here: https://lnkd.in/dsY6tsz2 

71

2 Kommentare

We hear it too often: healthcare systems are under immense cost pressure, and millions of patients still lack access to essential treatments. On October 13, I’ll be joining a panel of global health experts for the first ever @Sandoz Talking Biosimilars event, held at the World Health Summit in Berlin, in partnership with IQVIA. This discussion comes at a pivotal moment for healthcare systems worldwide. Over the next decade, biologic medicines worth more than USD 300 billion in peak sales are due to lose exclusivity. In Europe alone, an IQVIA study estimates that 110 biologics will lose IP protection by end 2032. However, the same study shows that approx. 80% of these products by value are currently unlikely to face competition, resulting in a missed opportunity for payers and patients: the so-called ‘biosimilar void’. Bringing together stakeholders from across the healthcare ecosystem, the session aims to drive action to address the biosimilar void and expand patient access to biosimilars. I’m looking forward to exchanging ideas with leaders who share our commitment to access and equity. 🔗 Register now to join online and in-person: https://lnkd.in/eCcX5jGV #WHS2025 #PioneeringAccess

345

4 Kommentare